Nanotechnology Now

Our NanoNews Digest Sponsors



Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > Cerulean Pharma Inc. Appoints Two Senior Executives to Management Team

Abstract:
Company Appoints John Ryan, Ph.D., M.D., to serve as Senior Vice President, Chief Medical Officer, and Karen Roberts to serve as Senior Vice President, Finance and Administration

Cerulean Pharma Inc. Appoints Two Senior Executives to Management Team

Cambridge, MA | Posted on March 10th, 2010

Cerulean Pharma Inc., a biopharmaceutical company focused on novel intelligently designed nanoparticle-based drugs, today announced the appointment of John Ryan, Ph.D., M.D., to serve as Senior Vice President, Chief Medical Officer and the appointment of Karen Roberts to serve as Senior Vice President, Finance and Administration. Both appointments are newly established roles that reflect Cerulean's growth and are effective immediately.

John Ryan has more than 20 years of experience in clinical research and development at AVEO Pharmaceuticals, Wyeth (formerly Genetics Institute), and Merck Research Laboratories. Most recently, Dr. Ryan served as Chief Medical Officer at AVEO Pharmaceuticals, Inc., where he built a clinical group for the development of oncology drugs. Prior to working in clinical development in the pharmaceutical industry, Dr. Ryan held Associate Professorships at both the University of Pennsylvania School of Medicine and Yale University School of Medicine. He holds a Ph.D. in Molecular Biophysics from Yale University and an M.D. from the University of California at San Diego.

Karen Roberts joins Cerulean after serving as Vice President, Finance and Administration at Elixir Pharmaceuticals, Inc., since Elixir's founding in 2001. At Elixir, Ms. Roberts was a core member of the executive management team and responsible for all aspects of accounting, finance and administration for that company. Prior to joining Elixir, Ms. Roberts held senior financial positions, where she was responsible for financial operations, at Frontline Group, Dyax Corporation and T Cell Sciences. Ms. Roberts was originally recruited into the life sciences field from Avery Dennison Corporation, where she held numerous financial positions of increasing responsibility. She holds a B.S. in Business Administration from Salem State College.

"We are tremendously excited about Dr. Ryan's transition from Acting Chief Medical Officer to Senior Vice President, Chief Medical Officer. His appointment to this position will assist us in aggressively advancing IT-101 in clinical development and in strategically progressing our growing pipeline into clinical development," said Dr. Oliver Fetzer, President and CEO of Cerulean.

"In addition, the appointment of Ms. Roberts, who has depth of experience in the life sciences industry, to the management team will provide Cerulean with key financial strategic guidance as we position the Company to become a leader in nanopharmaceuticals," said Dr. Fetzer.

####

About Cerulean Pharma
Cerulean Pharma Inc. is a privately-held biopharmaceutical company focused on the development of novel nanotechnology-based therapeutics in the areas of oncology, cardiovascular, autoimmune and inflammatory diseases. The Company has assembled a world-class management team, board of directors and scientific advisory board that collectively have a significant track record of business building, product development and scientific breakthroughs from leadership companies and institutions. The company has been funded by leading investors Polaris Venture Partners, Venrock, Lux Capital, Bessemer Venture Partners, Alexandria Real Estate Equities, and William H. Rastetter. Cerulean is located in Cambridge, Massachusetts.

For more information, please click here

Contacts:
Cerulean Pharma Inc.
840 Memorial Drive, 5th Floor
Cambridge, MA 02139
Tel 617-551-9600
Fax 617-494-1544

All inquiries:

Copyright © Cerulean Pharma

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Stressed Out: Research Sheds New Light on Why Rechargeable Batteries Fail October 1st, 2014

New Absorber Will Lead to Better Biosensor: Biosensors are more sensitive and able to detect smaller changes in the environment October 1st, 2014

Graphene chips are close to significant commercialization October 1st, 2014

Production of Filters for Separation of Water from Petroleum Products in Iran October 1st, 2014

Announcements

Stressed Out: Research Sheds New Light on Why Rechargeable Batteries Fail October 1st, 2014

New Absorber Will Lead to Better Biosensor: Biosensors are more sensitive and able to detect smaller changes in the environment October 1st, 2014

Graphene chips are close to significant commercialization October 1st, 2014

Production of Filters for Separation of Water from Petroleum Products in Iran October 1st, 2014

Appointments/Promotions/New hires/Resignations/Deaths

NREL Announces New Center Directors to lead R&D, Analysis Efforts September 30th, 2014

Jeff Andreson to Join Nanometrics as Chief Financial Officer September 4th, 2014

New Vice President Takes Helm at CNSE CMOST: Catherine Gilbert To Lead CNSE Children’s Museum of Science and Technology Through Expansion And Relocation August 29th, 2014

Nanometrics CFO to Resign for New Job Opportunity August 8th, 2014

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE